Morphic Holding, Inc. (MORF)

Last Price: 26.07 (2020-07-01)

Company Description

Morphic Holding Inc. is a biopharmaceutical company. It focuses on the discovery and development of oral small-molecule integrin therapeutics for autoimmune, cardiovascular and metabolic diseases, as well as fibrosis and cancer. Morphic Holding Inc. is based in Waltham, Massachusetts.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $16.98M
Net Income (Most Recent Fiscal Year) $-43.33M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 6.40
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -328.72%
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -60.56%
Return on Assets (Trailing 12 Months) -23.98%
Current Ratio (Most Recent Fiscal Quarter) 6.12
Quick Ratio (Most Recent Fiscal Quarter) 6.12
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $4.62
Earnings per Share (Most Recent Fiscal Quarter) $-0.55
Earnings per Share (Most Recent Fiscal Year) $-2.69
Diluted Earnings per Share (Trailing 12 Months) $-6.24
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 30.60M
Free Float 18.52M
Market Capitalization $827.81M
Average Volume (Last 20 Days) 0.16M
Beta (Past 60 Months) --
Percentage Held By Insiders (Latest Annual Proxy Report) 39.50%
Percentage Held By Institutions (Latest 13F Reports) 57.30%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%